ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1233

A Descriptive Analysis of Real-World Treatment Patterns of Innovator Infliximab (Remicade) and Biosimilar Infliximab in a Treatment NaïVe Turkish Rheumatologic Disease Population

Yusuf Yazici1, Lin Xie2, Adesuwa Ogbomo3, Dennis Parenti4, Kavitha Goyal4, Amanda Teeple4, Lorie A. Ellis5 and Ismail Simsek6, 1New York University, Hospital of Joint Diseases, New York, NY, 2SATinMED Research, Ann Arbor, MI, 3STATinMED Research Inc., Ann Arbor, MI, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, 6Guven Hospital, Ankara, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: rheumatic disease and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Session Title: Health Services Research - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: This retrospective healthcare claims analysis examined treatment patterns of innovator infliximab (IFX) and biosimilar infliximab (CT-P13) in a Turkish rheumatologic disease population after CT-P13 availability in July, 2014.

Methods:   Adult patients (pts) with ≥1 diagnosis code (ICD-10-CM) for rheumatoid arthritis (RA) were identified in a national Turkish healthcare database during the study period (01DEC2010-01DEC2015).  Eligible pts had continuous medical/pharmacy enrollment ≥12 months before and ≥6 months after IFX or CT-P13 initiation (index date). Patients were naïve to IFX or CT-P13 (i.e. had no IFX or CT-P13 within 12 months before the index date). Demographics, concomitant diseases and medications, and treatment patterns, eg., dose, interval, discontinuation, and switch were summarized. Confirmed discontinuation was defined as a switch to another biologic medication or the absence of an index biologic claim for ≥120 days without censoring.

Results: Key results are shown in the Table.  A total of 1044 patients initiated either medication. The majority (80%; n=831) initiated IFX. The IFX cohort had a mean age of 42 years; 56% were women and mean follow up was 12 months.  The CT-P13 cohort consisted of 213 pts with mean age of 43 years; 58% women; and mean follow up of 9 months. Approximately one-third of pts in each cohort had a concomitant diagnosis of ankylosing spondylitis (AS; TABLE).  Other concomitant diseases and medications appeared balanced between cohorts. Pts in the IFX cohort had an average of 5.2 infusions and mean dose of 4.7 vials per infusion approximately every 8 weeks. Pts in the CT-P13 cohort had an average of 3.6 doses and mean dose of 5.8 vials per dispensing approximately 9 weeks apart. A confirmed discontinuation occurred in 55% of the IFX cohort; driven in part by switching.  24% of IFX pts had ≥ 1 biologic switch with 8% initially switching to CT-P13.  Time to any discontinuation or censoring of IFX is shown in the Figure and Table. In the CT-P13 cohort, a confirmed discontinuation was observed in 63%; 31% switched to another biologic therapy; and 20% initially switched to IFX. Time to any discontinuation or censoring of CT-P13 is shown in Figure and Table.

Conclusion: These findings in a single country indicate that real world utilization patterns may differ between innovator IFX and CT-P13, with predominantly more patients initiating IFX; greater overall CT-P13 discontinuation and a higher proportion of patients switching from CT-P13 to IFX. Further studies are needed to understand the reasons for these observed differences. Table

 

Innovator IFX Cohort

CT-P13Cohort

 

(N= 831)

(N=213 )

 

N/Mean

%/SD

N/Mean

%/SD

Age (Mean)

42

13

43

12

Gender

Female

465

56%

124

58 %

Average Length of Follow up Period ( in Months)

12

3

9

2

Concomitant Disease During Baseline Period

 

 

 

 

Ankylosing Spondylitis

230

28%

70

33%

Psoriatic Arthritis

130

16%

24

11%

Crohn’s Disease

65

8%

11

5%

Ulcerative Colitis

64

8%

10

5%

Concomitant RA-Medications During Follow up Period

Methotrexate

253

30%

69

32%

Sulfasalazine

147

18%

46

22%

Dosing Characteristics

 

 

 

 

Average # of doses within  follow up period

5.2

2.6

3.6

1.8

Mean # of  weeks between doses

8.2

4.2

9.0

4.7

Mean # of days between 1st and 2nd dose

38

37

50

41

Mean # of days between 2nd and 3rd dose

53

33

60

38

Mean # of days between 3rd and 4th dose

65

34

67

31

Switching

 

 

 

 

# and % of patients with  ≥1  switch

203

24%

66

31%

# of patient switches between Infliximab Types

 

 

 

 

Switch to CT-P13

64

8%

Switch to Innovator  Infliximab

42

20%

Discontinuations

 

 

 

 

# of Patients Confirmed to Have Discontinued

453

55%

134

63%

Time to confirmed discontinuation (days)

155

93

107

66

Time to any discontinuation or censoring (days):

239

130

169

102

 


Disclosure: Y. Yazici, Janssen Scientific Affairs, LLC, 2; L. Xie, Janssen Scientific Affairs, LLC, 5; A. Ogbomo, Janssen Scientific Affairs, LLC, 5; D. Parenti, Janssen Scientific Affairs, LLC, 3; K. Goyal, Janssen Scientific Affairs, LLC, 3; A. Teeple, Janssen Scientific Affairs, LLC, 3; L. A. Ellis, Janssen Scientific Affairs, LLC, 3; I. Simsek, Janssen Scientific Affairs, LLC, 2.

To cite this abstract in AMA style:

Yazici Y, Xie L, Ogbomo A, Parenti D, Goyal K, Teeple A, Ellis LA, Simsek I. A Descriptive Analysis of Real-World Treatment Patterns of Innovator Infliximab (Remicade) and Biosimilar Infliximab in a Treatment NaïVe Turkish Rheumatologic Disease Population [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-descriptive-analysis-of-real-world-treatment-patterns-of-innovator-infliximab-remicade-and-biosimilar-infliximab-in-a-treatment-naive-turkish-rheumatologic-disease-population/. Accessed August 12, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-descriptive-analysis-of-real-world-treatment-patterns-of-innovator-infliximab-remicade-and-biosimilar-infliximab-in-a-treatment-naive-turkish-rheumatologic-disease-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies